South Korean Won Leads Asian FX Losses as Dollar Rises 
Gold Prices Hold Near Seven-Week High as Markets Await U.S. Inflation Data 
Wall Street Slips as Oil Prices Surge 5% on Iran-Hormuz Uncertainty 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Canada, US Hold Fresh Trade Talks as August 19 Tariff Deadline Nears 
Yen Stabilizes After Intervention Slide as Australian Dollar Hits Eight-Week High 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Singapore Raises 2026 GDP Growth Forecast to 4.5%-5.5% as AI Boom Fuels Economy 
Asian Stocks Mixed as RBA Holds Rates, Oil Risks Rise 
England Drought Expands to 71% as Heatwave Deepens Water Crisis 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Oil, Gold Rise as Geopolitical Risks Grip Markets Ahead of U.S. CPI 
Johnson & Johnson acquires Abiomed medical device technology company that develops and manufactures temporary external and implantable mechanical circulatory support devices such as the heart pump. The company invested $16.6 million in the acquisition deal.
Johnson & Johnson revealed its latest investment on Tuesday, Nov. 1, and it was described as its biggest purchase in almost six years. The buyout was a strategic move as the company is looking to bolster its cardiovascular business.
It was noted that the decision was made at a time when Johnson & Johnson was spinning off its consumer health business unit so it could focus on works related to pharmaceuticals and medical devices. The addition of Abiomed to its portfolio through the acquisition deal is expected to scale up its medical device division.
As part of the agreement, the company will pay $380 for each Abiomed share. It will also hand out another $35 per share in cash if the Danvers, Massachusetts-headquartered medical device maker achieves new commercial and clinical milestones, as per CNBC.
Abiomed is known to develop heart pumps and other technology for the treatment of coronary artery disease and heart failure. Its Impella heart pump device is typically used for patients suffering from severe coronary artery disease.
This Johnson & Johnson and Abiomed acquisition agreement is expected to be completed by early next year. Once done, it will help J&J broaden its position as a thriving cardiovascular innovator while also building its medical device segment.
“The addition of Abiomed is an important step in the execution of our strategic priorities and our vision for the new Johnson & Johnson focused on Pharmaceutical and MedTech,” Johnson & Johnson’s chief executive officer, Joaquin Duato, said in a press release.
The CEO added, “We have committed to enhancing our position in MedTech by entering high-growth segments. The addition of Abiomed provides a strategic platform to advance breakthrough treatments in cardiovascular disease and helps more patients around the world while driving value for our shareholders.”
Finally, Johson & Johnson said that Abiomed will be placed under its medical technology unit but that, despite the acquisition, it will continue to operate as a standalone business.
